Portfolio Members
The following companies are part of the Medway Enterprise Hub business portfolio
Showing page 1 of 4
Medical Equipment
Bedfont Scientific Limited address
105 Laker Road, Rochester Airport Industrial Estate, Rochester, Kent, ME1 3QX
telephone
01634 673720
email
ask@bedfont.com - send email
website
http://www.bedfont.com - view
Bedfont Scientific has become a market leader in breath monitoring for medical applications. Its Smokerlyzer range of carbon monoxide monitors is used by health professionals throughout the world and is recognised as the market leader in smoking cessation and research.
As well as breath monitoring, Bedfont has a strong background in the use of precision gases. It was a key OEM supplier of calibration gas mixtures, sold internationally to manufacturers of safety, environmental, emissions, and medical gas monitoring systems. In October 2004 this activity was sold to a major UK gas company, allowing more freedom to focus on the medical products within the business.
Medical Equipment
Cambridge Research Systems address
80 Riverside, Sir Thomas Longley Road, Rochester, Kent, ME2 4BH
telephone
01634 720707
email
carol.luscombe@crsltd.com - send email
website
http://www.crsltd.com - view
Cambridge Research Systems has established a reputation founded on values of scientific rigour and integrity.
By combining engineering expertise with innovation and cutting edge technology, we aspire to design and develop tools that allow the advancement of vision science throughout the world.
Our products are market leaders, our people, committed and knowledgeable. Our ambition is to continue setting standards in the vision science community of which we are proud to be a part.
Cambridge Research Systems has developed a range of hardware and software tools for the advancement of vision science. Visual Stimulus Generators, or VSGs, are now complemented a full portfolio of equipment.
Environmental Technologies
Cantium Energy Ltd address
Medway Enterprise Hub, University of Greenwich at Medway, Chatham Maritime, Chatham, Kent, ME4 4TB
telephone
01634 883615
email
info@cantiumenergy.co.uk - send email
website
http://www,cantiumenergy.co.uk - view
Cantium is an Energy Services Company: a business that installs and operates heating and generating plant within customers’ buildings. We make the capital investment and sell the electricity and the heat we produce to the occupier. Most importantly, we only use local renewable fuels, so the heat and power we supply is 100% green. This is a very low cost way to replace expensive oil or gas heating and, because CHP is so efficient, can really make a difference to reducing Greenhouse Gases.
Environmental Technologies
Carbon8 Systems Limited address
Medway Enterprise Hub, University of Greenwich, Chatham Maritime, Kent, ME4 4TB
telephone
020 8331 9848
email
info@c8s.co.uk - send email
website
http://www.c8s.co.uk - view
Carbon8 Systems utilises an innovative, patented solution called Accelerated Carbonation Technology (ACT) that is a rapid, cost effective treatment suitable for soil and waste. ACT can be used in both on-site and off-site operations and can be integrated into existing industrial processes. ACT is a controlled accelerated version of the naturally occurring carbonation process, which results in an improvement in the chemical and physical properties of the treated materials. The technology can utilise waste CO2 emissions from local sources, capturing significant volumes of CO2. When carbonation is used in the recovery and recycling of waste, an end product with value is created.
Pharmaceuticals
Centrion Therapeutics Limited address
Medway Enterprise Hub, University of Greenwich, Chatham Maritime, Chatham, Kent , ME4 4TB
telephone
0208 331 8221
email
M.J.Leach@gre.ac.uk - - send email
Centrion Therapeutics is a University of Greenwich spin-out, which was founded by Dr Mike Leach and Dr Laurence Harbidge, who are both scientists at the School of Science. Centrion Therapeutics specialises in the synthesises and early development of novel agents aimed at the treatment of central nevous system disorders, for example multiple sclerosis and epilepsy. Potentially the compounds offer more potency than the current drugs for the treatment of these conditions.
